Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus POLYMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus POLYMOX.
OMNIPEN-N vs POLYMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
Amoxicillin is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity, leading to cell lysis.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life = 1-1.5 hours in adults; prolonged in renal impairment (up to 12-20 hours in anuria)
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Renal (70-80% unchanged via tubular secretion and glomerular filtration); biliary/fecal (small amount, <5%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic